European Primary Care Cardiovascular Society

2019 ESC guidelines on diabetes, pre-diabetes and CVD

10' education - Dec. 2, 2020 - Prof. Francesco Cosentino, MD

CVD prevention with GLP-1 receptor agonists

10' education - Nov. 10, 2020 - Prof. Kamlesh Khunti, MD

To achieve lower LDL-c goals, combination therapy is necessary

3' education - Oct. 28, 2020 - Prof. Kausik Ray, MD

Reducing CV risk in diabetes in primary care

10' education - Oct. 27, 2020 - Prof. Richard Hobbs, MD

Primary outcome reduced by anti-inflammatory drug in chronic coronary disease

3' education - Sep. 30, 2020 - Mark Nidorf, MD

Temporarily suspending or continuing ACEi/ARBs in hospitalized patients with COVID-19

3' education - Sep. 30, 2020 - Prof. Renato D. Lopes, MD, PhD

Consideration of BP lowering irrespective of prior CVD or baseline SBP

3' education - Sep. 30, 2020 - Kazem Rahimi, MD

Changes in the 2020 AF guidelines

3' education - Sep. 30, 2020 - Prof. Isabelle van Gelder, MD

All three end points show benefit with another SLGT2 inhibitor in HFrEF

3' education - Sep. 16, 2020 - Milton Packer, MD

SGLT2i provides nephroprotective effects in CKD patients

3' education - Sep. 16, 2020 - Prof. Hiddo Heerspink, PhD

Improved outcomes with early rhythm control in AF

3' education - Sep. 16, 2020 - Prof. Paulus Kirchhof, MD

Proportion of unrecognized MI greater in women

5' education - Aug. 19, 2020 - Yldau van der Ende, MD, PhD

Recovered COVID-19 patients and cardiac abnormalities

3' education - Aug. 19, 2020 - Prof. Rudolf de Boer, MD, PhD

How to detect familial hypercholesterolemia

10' education - July 29, 2020 - Rens Reeskamp, MD

Screening for familial hypercholesterolemia - why and how?

10' education - July 27, 2020 - Prof. Kees Hovingh, MD, PhD

Need for early detection of familial hypercholesterolemia

10' education - July 22, 2020 - Bert Wiegman, MD, PhD

More out-of-hospital cardiac arrest during COVID-19 outbreak in Lombardy, Italy

3' education - June 18, 2020 - Enrico Baldi, MD

Screening for AF, HF and CAD in primary care

5' education - June 16, 2020 - Victor Zwartkruis
Lecture 1 out of 3

COVID-19, ACE2 and RAASi - a scientific perspective

10' education - May 14, 2020 - Prof. Jan Danser, PhD
Lecture 2 out of 3

COVID-19, ACE2 and RAASi - a clinical perspective

10' education - May 14, 2020 - Prof. Murray Epstein, MD

2019 ESC guidelines on diabetes, pre-diabetes and CVD

10' education - Dec. 2, 2020 - Prof. Francesco Cosentino, MD
The recommendations in the 2019 ESC guidelines on management of diabetes and CVD have shifted from a glucose-centric approach towards an event-driven approach.

The recommendations in the 2019 ESC guidelines on management of diabetes and CVD have shifted from a glucose-centric approach towards an event-driven approach.

CV outcomes and all-cause death not reduced with omega-3 FA in elderly MI patients

News - Nov. 26, 2020

AHA 2020 The OMEMI trial found no beneficial effects on CV outcomes and all-cause death by omega-3 fatty acid supplementation in elderly patients after MI, compared to patients receiving placebo.

Kidney and CV risk reduction with nonsteroidal MRA in T2DM patients with CKD

News - Nov. 26, 2020

AHA 2020 The nonsteroidal MRA finerenone, evaluated in the FIDELIO-DKD trial, reduced the risk on renal and CV outcome compared to placebo in CKD and T2DM patients with or without a history of CVD.

Reduction CV events with polypill and aspirin in primary prevention setting

News - Nov. 26, 2020

AHA 2020 In individuals with intermediate CV risk and without CVD history, a combination of polypill plus aspirin reduced the primary outcome of CVD events compared to double placebo.

No effect on MACE outcomes with high dose omega-3 carboxylic acid

News - Nov. 26, 2020

AHA 2020 The STRENGTH trial found that omega-3 carboxylic acid supplementation had no beneficiary MACE outcome in patients with established or high-risk of CVD compared to placebo.

In patients who previously discontinued statins due to side effects, nocebo effect was present

News - Nov. 26, 2020

AHA 2020 The SAMSON trial showed that 90% of symptom burden in patients who previously discontinued statins is elicited by placebo tablets.

Reduction of total HF hospitalizations by IV ferric carboxymaltose in patients with acute HF and iron deficiency

News - Nov. 26, 2020

AHA 2020 Although the primary endpoint was just missed in the AFFIRM-AHF trial, the individual endpoint of total HF hospitalization was reduced by IV ferric carboxymaltose compared to placebo in patients with acute HF and iron deficiency.

In 4 out of 10 Swedish individuals presence of silent CAD

News - Nov. 26, 2020

AHA 2020 Prevalence of CAD in a Swedish population was 4 out of 10, using CCTA data from the SCAPIS cohort. A prediction model was developed to identify those with widespread atherosclerosis.

CVD prevention with GLP-1 receptor agonists

10' education - Nov. 10, 2020 - Prof. Kamlesh Khunti, MD
There are barriers to intensify treatment in T2DM patients leading to poor outcomes. Prof. Khunti presents findings from studies with GLP-1RA as a new, effective treatment option for T2DM patients with high CV risk.

There are barriers to intensify treatment in T2DM patients leading to poor outcomes. Prof. Khunti presents findings from studies with GLP-1RA as a new, effective treatment option for T2DM patients with high CV risk.

Increased risk of incident CVD with high consumption of sugary and light drinks

Literature - Nov. 6, 2020 - Chazelas E, et al. - J Am Coll Cardiol 2020
In a prospective study using data of a large French cohort, high consumption of sugary drinks and artificially-sweetened beverages increased risk of CVD.

In a prospective study using data of a large French cohort, high consumption of sugary drinks and artificially-sweetened beverages increased risk of CVD.

Proteomic-based CV prediction model for primary prevention

Literature - Oct. 29, 2020 - Hoogeveen RM, et al. - Eur Heart J 2020

A protein-based risk prediction model significantly improved CV risk assessment compared to a clinical risk model with traditional risk factors in a setting of primary prevention, especially in the first 3 years.

Higher risk of all-cause mortality in AF with nonrecommended dosing of NOACs

Literature - Oct. 29, 2020 - Camm AJ et al. - J Am Coll Cardiol 2020

In the GARFIELD-AF registry, most AF patients received recommended doses of NOAC. Those with nonrecommended doses (underdosing or overdosing) had increased risk of mortality compared to those with recommended doses.